Low prevalence of most frequent pathogenic variants of six PARK genes in sporadic Parkinson's disease

Folia Neuropathologica

Volumn 52, Issue 1, 2014, Pages 22-29

  Garciá, Silvia ^a   Loṕez Hernández, Luz Berenice ^a   Suarez Cuenca, Juan Antonio ^a,b   Solano Rojas, Marlene ^a,c   Gallegos Arreola, Martha P ^d   Gama Moreno, Olga ^a,e   Valdez Anguiano, Paulina ^a,f   Canto, Patricia ^a   Dav́ila Maldonado, Luis ^g   Cuevas García, Carlos F ^b   Coral Vázquez, Ramón Mauricio ^f  

^a CENTRO MÉDICO NACIONAL 20 DE NOVIEMBRE   (Mexico)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^c UNIVERSIDAD AUTÓNOMA DE GUERRERO   (Mexico)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA DE OCCIDENTE   (Mexico)

^e UNIVERSIDAD AUTÓNOMA DE GUADALAJARA   (Mexico)

^f INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^g Instituto Nacional de Ciencias Médicas de la Nutrición Salvador Zubirán   (Mexico)

Author keywords

LRRK2; Mexican mestizos; PARK2; Parkinson's disease

Indexed keywords

AMANTADINE; ARGININE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DJ 1 PROTEIN; GLYCINE; LEUCINE RICH REPEAT KINASE 2; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; PARKIN; SERINE; LRRK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; UBIQUITIN PROTEIN LIGASE;

ADULT; AGED; ARTICLE; ATP13A2 GENE; CONTROLLED STUDY; DJ 1 GENE; EXON; FEMALE; GENE; GENE DELETION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; LEUCINE RICH REPEAT KINASE 2 GENE; MAJOR CLINICAL STUDY; MALE; MESTIZO; MEXICO; MIDDLE AGED; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; PARK GENE; PARKIN GENE; PARKINSON DISEASE; PINK1 GENE; PREVALENCE; RISK FACTOR; SNCA GENE; TREATMENT RESPONSE; CROSS-SECTIONAL STUDY; GENETIC PREDISPOSITION; GENETICS; MULTIPLEX POLYMERASE CHAIN REACTION; NUCLEOTIDE SEQUENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AGED; CROSS-SECTIONAL STUDIES; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HUMANS; MALE; MEXICO; MIDDLE AGED; MULTIPLEX POLYMERASE CHAIN REACTION; PARKINSON DISEASE; PREVALENCE; PROTEIN-SERINE-THREONINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; UBIQUITIN-PROTEIN LIGASES;

EID: 84899544064     PISSN: 16414640     EISSN: 1509572X     Source Type: Journal    
DOI: 10.5114/fn.2014.41741     Document Type: Article

References (41)

1. Benitez BA, Forero DA, Arboleda GH, Granados LA,Yunis JJ, Fernandez W, Arboleda H. Exploration of genetic susceptibility factors for Parkinson's disease in a South American sample. J Genet 2010; 89: 229-232.
2. Buschman E, Skamene E. Linkage of leprosy susceptibility to Parkinson's disease genes. Int J Lepr Other Mycobact Dis 2004; 72: 169-170. (Pubitemid 39006892)
3. Cardoso CC, Pereira AC, de Sales Marques C, Moraes MO. Leprosy susceptibility: genetic variations regulate innate and adaptive immunity, and disease outcome. Future Microbiol 2011; 6: 533-549.
4. de Ynigo-Mojado L, Martin-Ruiz I, Sutherland JD. Efficient allele-specific targeting of LRRK2 R1441 mutations mediated by RNAi. PLoS One 2011; 6: e21352.
5. Feder J, Ovadia O, Glaser B, Mishmar D. Ashkenazi Jewish mtDNA haplogroup distribution varies among distinct subpopulations: lessons of population substructure in a closed group. Eur J Hum Genet 2007; 15: 498-500. (Pubitemid 46487706)
6. Fung HC, Chen CM, Hardy J, Singleton AB, Wu YR. A common genetic factor for Parkinson disease in ethnic Chinese population in Taiwan. BMC Neurol 2006; 6: 47.
7. Gatto EM, Parisi V, Converso DP, Poderoso JJ, Carreras MC, Marti-Masso JF, Paisan-Ruiz C. The LRRK2 G2019S mutation in a series of Argentinean patients with Parkinson's disease: clinical and demographic characteristics. Neurosci Lett 2013; 537: 1-5.
8. Gaweda-Walerych K, Safranow K, Jasinska-Myga B, Bialecka M, Klodowska-Duda G, Rudzinska M, Czyzewski K, Cobb SA, Slawek J, Styczynska M, Opala G, Drozdzik M, Nishioka K, Farrer MJ, Ross OA, Wszolek ZK, Barcikowska M, Zekanowski C. PARK2 variability in Polish Parkinson's disease patients - interaction with mitochondrial haplogroups. Parkinsonism Relat Disord 2012; 18: 520-524.
9. Gloeckner CJ, Schumacher A, Boldt K, Ueffing M. The Parkinson disease-associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, in vitro. J Neurochem 2009; 109: 959-968.
10. Gujral N, Freeman HJ, Thomson AB. Celiac disease: prevalence, diagnosis, pathogenesis and treatment. World J Gastroenterol 2012; 18: 6036-6059.
11. Gustincich S, Manfioletti G, Del Sal G, Schneider C, Carninci P. A fast method for high-quality genomic DNA extraction from whole human blood. Biotechniques 1991; 11: 298-300, 302.
12. Hakimi M, Selvanantham T, Swinton E, Padmore RF, Tong Y, Kabbach G, Venderova K, Girardin SE, Bulman DE, Scherzer CR, LaVoie MJ, Gris D, Park DS, Angel JB, Shen J, Philpott DJ, Schlossmacher MG. Parkinson's disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures. J Neural Transm 2011; 118: 795-808.
13. Healy DG, Falchi M, O'Sullivan SS, Bonifati V, Durr A, Bressman S, Brice A, Aasly J, Zabetian CP, Goldwurm S, Ferreira JJ, Tolosa E, Kay DM, Klein C, Williams DR, Marras C, Lang AE, Wszolek ZK, Berciano J, Schapira AH, Lynch T, Bhatia KP, Gasser T, Lees AJ, Wood NW. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 2008; 7: 583-590.
14. Healy DG, Wood NW, Schapira AH. Test for LRRK2 mutations in patients with Parkinson's disease. Pract Neurol 2008; 8: 381-385.
15. Huerta C, Castro MG, Coto E, Blazquez M, Ribacoba R, Guisasola LM, Salvador C, Martinez C, Lahoz CH, Alvarez V. Mitochondrial DNA polymorphisms and risk of Parkinson's disease in Spanish population. J Neurol Sci 2005; 236: 49-54. (Pubitemid 41218692)
16. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002; 125: 861-870. (Pubitemid 34279780)
17. Kochanski A. Pathogenic mutations and non-pathogenic DNA polymorphisms in the most common neurodegenerative disorders. Folia Neuropathol 2007; 45: 164-169. (Pubitemid 351149041)
18. Kumari U, Tan EK. LRRK2 in Parkinson's disease: genetic and clinical studies from patients. FEBS J 2009; 276: 6455-6463.
19. Liu X, Cheng R, Verbitsky M, Kisselev S, Browne A, Mejia-Sanatana H, Louis ED, Cote LJ, Andrews H, Waters C, Ford B, Frucht S, Fahn S, Marder K, Clark LN, Lee JH. Genome-wide association study identifies candidate genes for Parkinson's disease in an Ashkenazi Jewish population. BMC Med Genet 2011; 12: 104.
20. Liu Z, Lee J, Krummey S, Lu W, Cai H, Lenardo MJ. The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel disease. Nat Immunol 2011; 12: 1063-1070.
21. Lohmann E, Periquet M, Bonifati V, Wood NW, De Michele G, Bonnet AM, Fraix V, Broussolle E, Horstink MW, Vidailhet M, Verpillat P, Gasser T, Nicholl D, Teive H, Raskin S, Rascol O, Destee A, Ruberg M, Gasparini F, Meco G, Agid Y, Durr A, Brice A. How much phenotypic variation can be attributed to parkin genotype? Ann Neurol 2003; 54: 176-185. (Pubitemid 36913573)
22. Lucking CB, Abbas N, Durr A, Bonifati V, Bonnet AM, de Broucker T, De Michele G, Wood NW, Agid Y, Brice A. Homozygous deletions in parkin gene in European and North African families with autosomal recessive juvenile parkinsonism. The European Consortium on Genetic Susceptibility in Parkinson's Disease and the French Parkinson's Disease Genetics Study Group. Lancet 1998; 352: 1355-1356.
23. Martinez HR, Gonzalez-Gonzalez H, Cantu-Martinez L, Ran-gel- Guerra R, Hernandez-Castillo CD, Vergara-Saavedra JJ, Ramos-Gonzalez MR, Cerda-Flores RM, Morales-Garza MA, Guerrero-Munoz MJ, Montes-de-Oca-Luna R, Saucedo-Cardenas O. PARKIN-coding polymorphisms are not associated with Parkinson's disease in a population from northeastern Mexico. Neurosci Lett 2010; 468: 264-266.
24. Moran JM, Castellanos-Pinedo F, Casado-Naranjo I, Duran-Herrera C, Ramirez-Moreno JM, Gomez M, Zurdo-Hernandez JM, Fuentes E, Ortiz-Ortiz MA, Moreno AD, Gonzalez-Polo RA, Niso-Santano M, Bravo-Sanpedro JM, Perez-Tur J, Ruiz-Mesa LM, Fuentes JM. Genetic screening for the LRRK2, G2019S and R1441 codon mutations in Parkinson's disease patients from Extremadura, Spain. Rev Neurol 2010; 50: 591-594.
25. Nuytemans K, Meeus B, Crosiers D, Brouwers N, Goossens D, Engelborghs S, Pals P, Pickut B, Van den Broeck M, Corsmit E, Cras P, De Deyn PP, Del-Favero J, Van Broeckhoven C, Theuns J. Relative contribution of simple mutations vs. copy number variations in five Parkinson disease genes in the Belgian population. Hum Mutat 2009; 30: 1054-1061.
26. Paisan-Ruiz C, Lang AE, Kawarai T, Sato C, Salehi-Rad S, Fis- man GK, Al-Khairallah T, St George-Hyslop P, Singleton A, Rogaeva E. LRRK2 gene in Parkinson disease: mutation analysis and case control association study. Neurology 2005; 65: 696-700. (Pubitemid 41285847)
27. Poorkaj P, Nutt JG, James D, Gancher S, Bird TD, Steinbart E, Schellenberg GD, Payami H. Parkin mutation analysis in clinic patients with early-onset Parkinson [corrected] disease. Am J Med Genet A 2004; 129A: 44-50. (Pubitemid 38989043)
28. Ramirez-Jirano LJ, Ruiz-Sandoval JL, Jimenez-Gil FJ, Ramirez-Vega J, Vargas-Frutos E, Gallegos-Arreola MP. Frequency of the IVS4+66A-G polymorphism in the alpha-synuclein gene in patients with Parkinson's disease in north-western Mexico. Rev Neurol 2007; 44: 15-17. (Pubitemid 350304982)
29. Rubi-Castellanos R, Martinez-Cortes G, Munoz-Valle JF, Gonzalez-Martin A, Cerda-Flores RM, Anaya-Palafox M, Rangel-Villalobos H. Pre-Hispanic Mesoamerican demography approximates the present-day ancestry of Mestizos throughout the territory of Mexico. Am J Phys Anthropol 2009; 139: 284-294.
30. Santos-Garcia D, Abella-Corral J, Aneiros-Diaz A, Santos-Canelles H, Llaneza-Gonzalez MA, Macias-Arribi M. Pain in Parkinson's disease: prevalence, characteristics, associated factors, and relation with other non motor symptoms, quality of life, autonomy, and caregiver burden. Rev Neurol 2011; 52: 385-393.
31. Satake W, Nakabayashi Y, Mizuta I, Hirota Y, Ito C, Kubo M, Kawaguchi T, Tsunoda T, Watanabe M, Takeda A, Tomiyama H, Nakashima K, Hasegawa K, Obata F, Yoshikawa T, Kawakami H, Sakoda S, Yamamoto M, Hattori N, Murata M, Nakamura Y, Toda T. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet 2009; 41: 1303-1307.
32. Slager SL, Schaid DJ. Case-control studies of genetic markers: power and sample size approximations for Armitage's test for trend. Hum Hered 2001; 52: 149-153. (Pubitemid 34701500)
33. Songin M, Ossowska K, Kuter K, Strosznajder JB. Alteration of GSK-3beta in the hippocampus and other brain structures after chronic paraquat administration in rats. Folia Neuropathol 2011; 49: 319-327.
34. Tabakman R, Lecht S, Lazarovici P. Neuroprotection by monoamine oxidase B inhibitors: a therapeutic strategy for Parkinson's disease? Bioessays 2004; 26: 80-90. (Pubitemid 38095352)
35. Tan EK, Zhao Y, Skipper L, Tan MG, Di Fonzo A, Sun L, Fook-Chong S, Tang S, Chua E, Yuen Y, Tan L, Pavanni R, Wong MC, Kolatkar P, Lu CS, Bonifati V, Liu JJ. The LRRK2 Gly2385Arg variant is associated with Parkinson's disease: genetic and functional evidence. Hum Genet 2007; 120: 857-863. (Pubitemid 46128841)
36. .Tomiyama H, Hatano T, Hattori N. Clinical molecular genetics for PARK8 (LRRK2)]. Brain Nerve 2007; 59: 839-850. (Pubitemid 47280223)
37. Torkaman-Boutorabi A, Ali Shahidi G, Choopani S, Reza Zarrindast M. Association of monoamine oxidase B and catechol-O-methyltransferase polymorphisms with sporadic Parkinson's disease in an Iranian population. Folia Neuropathol 2012; 50: 382-389.
38. van der Walt JM, Nicodemus KK, Martin ER, Scott WK, Nan- ce MA, Watts RL, Hubble JP, Haines JL, Koller WC, Lyons K, Pahwa R, Stern MB, Colcher A, Hiner BC, Jankovic J, Ondo WG, Allen FH Jr, Goetz CG, Small GW, Mastaglia F, Stajich JM, McLaurin AC, Middleton LT, Scott BL, Schmechel DE, Pericak-Vance MA, Vance JM. Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet 2003; 72: 804-811.
39. Wild P, Dikic I. Mitochondria get a Parkin' ticket. Nat Cell Biol 2010; 12: 104-106.
40. .Yescas P, Lopez M, Monroy N, Boll MC, Rodriguez-Violante M, Rodriguez U, Ochoa A, Alonso ME. Low frequency of common LRRK2 mutations in Mexican patients with Parkinson's disease. Neurosci Lett 2010; 485: 79-82.
41. Yun H, Heo HY, Kim HH, DooKim N, Seol W. Identification of chemicals to inhibit the kinase activity of leucine-rich repeat kinase 2 (LRRK2), a Parkinson's disease-associated protein. Bioorg Med Chem Lett 2011; 21: 2953-2957.